Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of trastuzumab deruxtecan plus bevacizumab versus bevacizumab alone as first-line maintenance for HER2-expressing ovarian cancer
MOH_2025-06-04_014123Phase 3Recruiting
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- May 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of trastuzumab deruxtecan and bevacizumab in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) (3 arms), sponsored by Daiichi Sankyo Co., Ltd. Started May 2025; status: recruiting.
02
Drugs
trastuzumab deruxtecanbevacizumab
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on MOH_2025-06-04_014123.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2025-06-04_014123.